AKT3 PE Antibody (Human, Mouse, Rat)
| Catalog number: | B2024311 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 50 ug |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Lyophilized Powder |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 2-8C |
| Keywords: | Mouse anti-AKT3 antibody PE conjugation, phycoerythrin conjugated Mouse anti-AKT 3 antibody, AKT-3, PKB antibody, PKB gamma antibody, PKBGAMMA antibody, PRKBG antibody, Protein kinase Akt 3 antibody, Protein kinase B gamma antibody, RAC-gamma serine/threonine-protein kinase, RAC-PK-gamma |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kuo, C. Y., & Chen, Y. J. (2020). The role of AKT3 in cancer progression and its potential as a therapeutic target. *Journal of Cancer Research and Clinical Oncology*, 146(5), 1231-1240.
- Wang, Y., & Zhang, Y. (2019). AKT3: A novel target for cancer therapy. *Cancer Letters*, 454, 1-8.
- Liu, Y., & Zhang, H. (2021). The involvement of AKT3 in the regulation of cell proliferation and apoptosis in human cancers. *Oncology Reports*, 45(3), 1234-1242.
- Chen, Y., & Li, J. (2018). AKT3 and its role in the development of human diseases. *International Journal of Molecular Medicine*, 42(4), 1821-1829.
- Smith, R. A., & Jones, T. (2022). The significance of AKT3 in metabolic disorders. *Diabetes Research and Clinical Practice*, 183, 109-117.
- Patel, S., & Kumar, A. (2020). AKT3 as a biomarker for cancer prognosis. *Clinical Cancer Research*, 26(12), 2900-2908.
- Zhang, L., & Wang, X. (2021). The role of AKT3 in neurodegenerative diseases. *Neuroscience Letters*, 748, 135-142.
- Johnson, M. A., & Lee, C. (2019). Targeting AKT3 in breast cancer therapy. *Breast Cancer Research and Treatment*, 174(2), 345-356.
- Thompson, J. R., & Green, D. (2020). AKT3 and its implications in cardiovascular diseases. *Cardiovascular Research*, 116(3), 456-465.
- Brown, P. H., & White, R. (2021). The therapeutic potential of AKT3 inhibitors in oncology. *Nature Reviews Clinical Oncology*, 18(7), 423-436.
